Top 5 Drug Type | Count |
---|---|
Small molecule drug | 8 |
Chemical drugs | 3 |
Target |
Mechanism AR antagonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism A3R agonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism 5-HT6 receptor antagonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Aug 2024 |
Sponsor / Collaborator |
Start Date01 Aug 2024 |
Sponsor / Collaborator ![]() [+3] |
Start Date13 May 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
VFP-B-3 ( PDE4 x PDE7 ) | Autoimmune Diseases More | Preclinical |
PZ-1727 ( 5-HT6 receptor ) | Neurodegenerative Diseases More | Preclinical |
NBD-14204 ( ITIH4 ) | Acute Myeloid Leukemia More | Preclinical |
compound 6i(National Institute of Technology) | Bacterial Infections More | Preclinical |
FKK6 | Inflammation More | Preclinical |